EUVIMEDOpdag EUVIMED
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects

Yusuke Tadayasu, Donald Sarubbi, Takumi Furuichi, Anastasia Eleftheraki, Shuhei Nakamura, Wiebke Sauter, Ryuzo Hanada

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16249 ↗

At a glance

Klinische Studie (Phase I) in British Journal of Clinical Pharmacology, 2025. Written by Yusuke Tadayasu and 6 co-authors. Institution: Nippon Boehringer Ingelheim Co. Ltd., Kobe, Japan. Major MEDLINE topics: Cathepsin C, Dose-Response Relationship, Drug. Cited 2 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Boehringer Ingelheim.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Bronchiectasis patients face an unmet need for treatment options that reduce inflammation. Cathepsin C inhibition is expected to achieve this by reducing the activation of neutrophil‐derived serine proteases. Here, we present safety and pharmacokinetic (PK) data from a Phase I trial evaluating the novel cathepsin C inhibitor BI 1291583 in healthy Japanese male subjects.

Methods

This randomized, double‐blind, placebo‐controlled, parallel‐group study investigated BI 1291583 in healthy Japanese male subjects (jRCT2071210111) and consisted of a single‐rising‐dose (SRD) part and a multiple‐dose (MD) part. The primary endpoint was the percentage of subjects with drug‐related treatment‐emergent adverse events (AEs). Secondary PK endpoints (SRD: AUC 0‐∞ and C max ; MD: AUC τ,1 and C max,1 after first dose and AUC τ,ss and C max,ss after last dose), as well as further safety and PK endpoints, were also assessed.

Results

Overall, 36 subjects ( n = 24 for SRD part; n = 12 for MD part) entered this Phase I trial. BI 1291583 was safe and well tolerated across the doses tested. All AEs were of mild intensity, with no drug‐related treatment‐emergent AEs, deaths, serious AEs or AEs of special interest reported in either part of the trial. Following both SRD and MD administration, BI 1291583 was readily absorbed, and PK was supraproportional over the doses assessed.

Conclusion

The results show that BI 1291583 has an appropriate benefit–risk ratio for Japanese patients, with no safety or exposure concerns at the doses studied. Japanese patients with bronchiectasis can be safely integrated into future global clinical trials of BI 1291583, with no dose adjustment required.

Subjects

MeSH terms (MEDLINE)

Cathepsin CDose-Response Relationship, DrugAdultHumansMaleMiddle AgedYoung AdultArea Under CurveDouble-Blind MethodEast Asian PeopleHealthy VolunteersJapanPharmacokinetics

Author keywords

drug safetyinflammationpharmacokineticsphase I

Substances

Cathepsin C

Authors and institutions

  • Nippon Boehringer Ingelheim Co. Ltd., Kobe, Japan.
  • Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
  • Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan.
  • Boehringer Ingelheim International GmbH, Biberach, Germany.
  • SOUSEIKAI Sumida Hospital, Tokyo, Japan.

Funding

  • Boehringer Ingelheim

Cite

APA

Tadayasu, Y., Sarubbi, D., Furuichi, T., Eleftheraki, A., Nakamura, S., Sauter, W., & Hanada, R. (2025). A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16249

Vancouver

Tadayasu Y, Sarubbi D, Furuichi T, Eleftheraki A, Nakamura S, Sauter W, et al. A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16249

BibTeX
@article{Tadayasu2025,
  author = {Tadayasu, Yusuke and Sarubbi, Donald and Furuichi, Takumi and Eleftheraki, Anastasia and Nakamura, Shuhei and Sauter, Wiebke and Hanada, Ryuzo},
  title = {A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16249}
}
Start for free →